Literature DB >> 32479569

Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2019        PMID： 32479569      PMCID： PMC6883444          DOI： 10.1159/000503254

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  45 in total

1.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

Review 2.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

3.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

4.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

Review 5.  FOXP3+ regulatory T cells in the human immune system.

Authors:  Shimon Sakaguchi; Makoto Miyara; Cristina M Costantino; David A Hafler
Journal:  Nat Rev Immunol       Date:  2010-06-18       Impact factor: 53.106

6.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

7.  Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Authors:  Mario Sznol; Lieping Chen
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

Review 8.  Control of the immune response by pro-angiogenic factors.

Authors:  Thibault Voron; Elie Marcheteau; Simon Pernot; Orianne Colussi; Eric Tartour; Julien Taieb; Magali Terme
Journal:  Front Oncol       Date:  2014-04-02       Impact factor: 6.244

Review 9.  Clinical impact of checkpoint inhibitors as novel cancer therapies.

Authors:  Kent Shih; Hendrik-Tobias Arkenau; Jeffrey R Infante
Journal:  Drugs       Date:  2014-11       Impact factor: 9.546

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307
View more
  12 in total

1.  Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-10-26       Impact factor: 11.740

2.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

Review 3.  Emerging Therapies in Penile Cancer.

Authors:  Antonio Machado Alencar; Guru Sonpavde
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

Review 4.  Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Cancers (Basel)       Date:  2020-04-27       Impact factor: 6.639

5.  Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.

Authors:  Yanan Peng; Chang Liu; Mengting Li; Wenjie Li; Mengna Zhang; Xiang Jiang; Ying Chang; Lan Liu; Fan Wang; Qiu Zhao
Journal:  Cancer Cell Int       Date:  2021-02-10       Impact factor: 5.722

6.  Integrated Proteomics and Bioinformatics to Identify Potential Prognostic Biomarkers in Hepatocellular Carcinoma.

Authors:  Qifan Zhang; Zhen Xiao; Shibo Sun; Kai Wang; Jianping Qian; Zhonglin Cui; Tao Tao; Jie Zhou
Journal:  Cancer Manag Res       Date:  2021-03-11       Impact factor: 3.989

7.  Bioinformatics Analysis Using ATAC-seq and RNA-seq for the Identification of 15 Gene Signatures Associated With the Prediction of Prognosis in Hepatocellular Carcinoma.

Authors:  Hui Yang; Gang Li; Guangping Qiu
Journal:  Front Oncol       Date:  2021-10-25       Impact factor: 6.244

8.  Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis.

Authors:  Changjing Huang; Chenyue Zhang; Jie Sheng; Dan Wang; Yingke Zhao; Ling Qian; Lin Xie; Zhiqiang Meng
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

Review 9.  Neoantigen: A New Breakthrough in Tumor Immunotherapy.

Authors:  Zheying Zhang; Manman Lu; Yu Qin; Wuji Gao; Li Tao; Wei Su; Jiateng Zhong
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

Review 10.  Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma.

Authors:  Landon L Chan; Stephen L Chan
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.